X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results

X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 24c

May 7, 2020 7:50 AM EDT

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of ($0.56), $0.24 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $3 million.

During these challenging and unprecedented times, our thoughts are with everyone affected by the COVID-19 pandemic, said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. Here at X4, we continue our efforts to advance our lead product candidate, mavorixafor, through clinical development. As... More